Skip to content

Patient experience and advocacy

TL;DR — Asthma burden is not captured by FEV1 or an annual attack count. People describe vigilance about the next attack, disrupted sleep, restricted exercise, school/work absence, embarrassment using inhalers, uncertainty about “preventer” benefit, medication cost and repeated efforts to be believed. Severe asthma adds oral-steroid toxicity, appointment and biologic burden, while apparently mild asthma can still produce fear and life-threatening attacks. Supported self-management reduces hospitalization and unscheduled care, but it works when paired with access, an agreed written action plan and regular review—not by transferring responsibility to the patient (Pinnock 2017, PMID 28302126). Advocacy priorities are objective diagnosis, affordable ICS-containing treatment, clean air, school/workplace safety, respectful shared decisions and outcomes that reflect participation and treatment burden.

What matters beyond “control”

Domain Questions worth asking
Safety “What do you fear might happen during an attack?”
Sleep “How does asthma—or worry about it—affect your sleep?”
Participation “What have you stopped doing at school, work, sport or socially?”
Treatment burden “What is hardest about taking or obtaining treatment?”
Identity/stigma “When do you avoid using an inhaler in front of others?”
Confidence “How sure are you about what to do when symptoms worsen?”
Trust “Have you felt believed and involved in decisions?”
Goals “What would a meaningful improvement let you do?”

Patient-selected goals do not always match clinician targets. In severe-asthma trial cohorts, only 53% aligned with clinician-defined goals; patients selected disease, function and knowledge goals, and goal achievement changed adherence behavior (Mulvey 2021, PMID 33577946).

The experience of attacks

Qualitative work in the United States and Germany found that “moderate” attacks affect activity, sleep, emotion and work even when they do not meet severe trial endpoints (Tabberer 2022, PMID 36414789). A binary hospitalized/not-hospitalized measure misses prolonged recovery and anticipatory anxiety.

Recent qualitative research found variable understanding of what constitutes an attack and when to escalate self-treatment, reinforcing the need to rehearse action plans rather than simply distribute them (Pradhan 2025, PMID 39773014).

Parents must make high-stakes decisions using noisy signs, prior experience, access and fear. Qualitative synthesis describes uncertainty about severity, competing household demands and thresholds for seeking urgent care (Goddard 2022, PMID 35967097).

A useful post-attack reconstruction

Moment Ask System response
Before What changed first? Was medication available? Identify triggers, access and delayed recognition
During What did you take and what happened? Correct plan, device and dose ambiguity
Decision Why did you seek—or delay—care? Address transport, cost, prior dismissal and childcare
Recovery How long until sleep/activity normalized? Capture burden beyond acute endpoint
Prevention What would make the next episode safer? Agree one feasible change and follow-up

Daily treatment: beliefs meet logistics

Adherence is not a stable personality trait. Qualitative synthesis identifies perceived necessity, concern about adverse effects/dependence, practical routines, clinician communication and social context as interacting influences (Lycett 2018, PMID 30053965; Amin 2020, PMID 32210541).

Young adults describe a tension between wanting an ordinary, spontaneous life and a daily regimen that makes chronic illness visible. Transitions in responsibility, changing routines and skepticism about benefit when asymptomatic all matter (Wadhahi 2022, PMID 34902272).

Patient statement Possible meaning Better clinician response
“I only need it when bad” Low perceived preventive benefit Link inflammation/attack risk to their history; discuss regimen options
“Steroids are dangerous” Real experience or generalized fear Separate inhaled and systemic exposure; quantify both benefits and harms
“I forget” Regimen does not fit routine Simplify, cue or change device collaboratively
“It runs out” Cost, refill, transport or supply failure Repair access rather than repeat education
“It does not work” Technique, wrong diagnosis or wrong outcome Observe use and define what response should look like
“I hate using it at school/work” Stigma or privacy barriers Plan discreet safe access and challenge discriminatory rules

Preference is clinically relevant. In a 351-person observational survey, 23.4% had a mismatch between preferred and current inhaler; matched preference was associated with better control, fewer attacks, less maintenance OCS and better adherence, although causality cannot be inferred (Nakanishi 2022, PMID 36316999).

Inhaler stigma and identity

Respiratory-disease stigma includes assumptions of weakness, contagion, smoking responsibility and attention-seeking (Rose 2017, PMID 28111991). Young people may conceal inhalers to protect social identity, trading immediate safety for belonging (Monaghan 2019, PMID 30461359).

Advocacy should target environments, not ask the individual to become invulnerable:

  • normalize inhaler use in schools and workplaces;
  • permit immediate reliever access;
  • train staff without disclosing more health information than necessary;
  • prohibit smoke/vaping and address occupational sensitizers;
  • design devices and storage that support privacy and portability;
  • use language that separates disease from blame.

Severe asthma and treatment burden

Qualitative research describes severe asthma as life-limiting and unpredictable, with work/family roles narrowed by symptoms and fatigue; “living well” depends on adapting goals and retaining agency, not only reducing a score (Stubbs 2019, PMID 31777564).

The path to severe-asthma diagnosis may involve years of repeated attacks, changing labels, steroid courses and disbelief. A 2024 qualitative study highlights diagnostic delay and fragmented care as part of the illness burden itself (Davis 2024, PMID 39184910).

Add-on pharmacotherapy brings hope but also injections/infusions, travel, scheduling, uncertainty about response and fear of stopping. Patients value fewer attacks, reduced OCS and restored participation, sometimes more than small lung-function changes (Clark 2021, PMID 33758515).

Oral corticosteroid burden

People weigh rapid relief against insomnia, mood change, appetite/weight effects, glucose/bone concerns and fear of cumulative harm. Reported concern about inhaled and oral corticosteroid adverse effects correlates with asthma-specific quality of life (Persaud 2023, PMID 37643678).

Patient and professional views on OCS include different tolerances for short-term relief versus long-term harm; decisions should display cumulative exposure and alternatives rather than treat each burst as isolated (McDonald 2025, PMID 40799034).

Children, caregivers and schools

Child and caregiver perspectives can diverge: children may prioritize sport, sleepovers and avoiding embarrassment; caregivers may prioritize attack prevention and monitoring (Kelada 2021, PMID 34504105).

Qualitative systematic review found that parents’ work includes recognizing symptoms, administering treatment, negotiating health services and managing school/childcare, often with uncertainty and disrupted sleep (Fawcett 2019, PMID 31090652).

After hospitalization, caregivers, clinicians and school nurses report barriers spanning communication, medication access, follow-up and unclear responsibility (Parikh 2018, PMID 30287588). A discharge plan that never reaches school is not a complete intervention.

Youth self-management education is valued when interactive, age-appropriate and connected to real situations; generic didactic programs can feel irrelevant (McTague 2022, PMID 36239214).

Minimum school safety standard

  1. accessible, in-date reliever with a spacer when indicated;
  2. current personalized action plan;
  3. staff able to recognize danger and activate emergency care;
  4. supported self-carry when legally and developmentally appropriate;
  5. asthma-friendly exercise participation, not unnecessary exclusion;
  6. communication among student, caregiver, clinician and designated staff;
  7. smoke/vape-free and occupationally safe environment.

Work and economic burden

Asthma costs include medication, consultations, transport and emergency care plus absence, reduced productivity and job constraints. Occupational asthma can force a choice between income and exposure avoidance.

Income is not a background demographic. A 2025 meta-analysis found people in the lowest versus highest income groups had higher odds of exacerbation, OR 1.25 (95% CI 1.13–1.37); estimates were 1.36 (1.23–1.50) in children and 1.19 (1.05–1.33) in adults (Gassasse 2025, PMID 40688041).

The correct response is not “improve adherence” in isolation. Ask whether the regimen is affordable, stocked, transportable, compatible with shifts, and covered between jobs.

Structural inequity

Asthma inequities reflect housing quality, pollution, occupational exposure, insurance/medicine access, primary care continuity, pharmacy supply and differential treatment within health systems. Race is not the biological cause of these patterns.

A US pediatric spatial systematic review included 40 studies; 37 found an association between at least one place-based social determinant and ED/hospital use. Poverty and environmental conditions were most studied, with consistent signals for housing quality, access, discrimination and crime among others (Tyris 2023, PMID 37455665).

Racial inequities appear in diagnosis, controller prescribing, specialty access and acute outcomes; measurement and intervention should focus on racism and system design rather than racial essentialism (Okelo 2022, PMID 36220057).

Black emerging adults with uncontrolled asthma describe transition, competing priorities and healthcare experiences that standard adherence instruments may miss (Lee 2024, PMID 37802253).

Equity checks for any intervention

Question Failure signal
Can people obtain the device every month? Improvement only among continuously insured participants
Does it require broadband/smartphone/data? Digital exclusion hidden as dropout
Is content linguistically/culturally usable? “Noncompliance” clustered by language
Can shift workers attend? Specialist benefit limited to daytime availability
Are pollution/housing hazards actionable? Advice without landlord/policy pathway
Who bears monitoring work? Caregiver burden increases without outcome gain

Shared decision-making

Shared decisions require exchange of evidence, options and values followed by an agreed action—not asking preference after selecting treatment.

A qualitative metasynthesis found that patient experience depends on clinician listening, understandable information, trust and genuine room to influence the plan (Kang 2024, PMID 38613765). A Cochrane review found limited heterogeneous trial evidence, so shared decision-making should be evaluated without reducing it to a checklist (Kew 2017, PMID 28972652).

In a vulnerable pediatric primary-care cohort, shared decision-making was associated with longer attack-free time, HR 0.56 (95% CI 0.29–1.08), but the confidence interval crossed 1 and residual confounding remains (Liu 2018, PMID 28892418).

Ask the patient to rank tradeoffs:

  • fewer attacks;
  • better day-to-day symptoms;
  • lower steroid exposure;
  • simpler dosing;
  • preferred device;
  • fewer appointments/injections;
  • lower cost;
  • pregnancy/reproductive considerations;
  • environmental footprint.

Measuring quality of life

Generic quality-of-life instruments may miss severe-asthma-specific burdens. The Severe Asthma Questionnaire was built with patient input and showed test–retest intraclass correlation 0.93 and internal consistency α=0.93 in validation, while discriminating treatment levels (Hyland 2018, PMID 29794132).

Patient-reported outcome selection should match purpose: control, asthma-specific quality of life, treatment burden, work productivity and caregiver burden are distinct. A score should support conversation, not replace it.

Supported self-management without abandonment

The effective package combines education, a personalized written action plan and regular professional review. A meta-review of 27 reviews and 244 RCTs found reduced hospitalization, emergency attendance and unscheduled care across diverse settings (Pinnock 2017, PMID 28302126).

Network meta-analysis similarly supports multicomponent self-management, but intervention labels and components vary (PMID 37500118). Self-management fails ethically when urgent care, medication and follow-up are unavailable.

Advocacy agenda

Level Priority
Individual care Objective diagnosis, respectful communication, shared goals and action plan
Clinic Same-day technique checks, refill/OCS visibility, post-attack follow-up
School/work Immediate reliever access, clean air, non-discrimination and accommodation
Health system Affordable ICS-containing medicines, spirometry and specialist pathways
Research Inclusive enrollment, patient-important endpoints and burden measurement
Policy Housing, pollution, tobacco/vaping and occupational exposure control

Patient preferences research identifies convenience, effectiveness, side effects and clinician relationship as central, but preferences are contextual and change with experience (Baggott 2020, PMID 32801203).

Open questions

  • Which patient-reported outcome set best captures fear, participation and treatment burden across severity?
  • How can action plans remain usable during panic, sleep disruption and limited literacy?
  • Which access interventions reduce the income gradient in attacks? (Gassasse 2025, PMID 40688041)
  • How should cumulative caregiver and digital-monitoring workload be measured?
  • Which policies most effectively reduce school/work stigma and unsafe reliever restriction?

References

  1. Stubbs MA, et al. Living well with severe asthma. Breathe. 2019. PMID 31777564
  2. Baggott C, et al. Patient preferences for asthma management: qualitative study. BMJ Open. 2020. PMID 32801203
  3. Kelada L, et al. Child and caregiver experiences of asthma self-management. J Asthma. 2021. PMID 34504105
  4. Parikh K, et al. Barriers and facilitators after asthma hospitalization. Hosp Pediatr. 2018. PMID 30287588
  5. Pradhan A, et al. Patient experience and self-management of asthma attacks. ERJ Open Res. 2025. PMID 39773014
  6. Lee JJ, et al. Black emerging adults with uncontrolled asthma: qualitative study. J Asthma. 2024. PMID 37802253
  7. Tabberer M, et al. Patient experience of moderate asthma attacks. J Asthma Allergy. 2022. PMID 36414789
  8. Lycett H, et al. Treatment perceptions and adherence in asthma. BMJ Open. 2018. PMID 30053965
  9. McTague K, et al. Youth experience of self-management education: qualitative evidence synthesis. Cochrane Database Syst Rev. 2022. PMID 36239214
  10. Amin S, et al. Patient perspectives on medication adherence: targeted qualitative review. Patient Prefer Adherence. 2020. PMID 32210541
  11. Wadhahi AA, et al. The lived experience of adherence to asthma medication in young adults (18–34 years). J Asthma. 2022. PMID 34902272
  12. Rose S, et al. Stigma in non-communicable respiratory disease: systematic review. Chron Respir Dis. 2017. PMID 28111991
  13. Monaghan LF, Gabe J. Young people, asthma and chronic-illness stigma. Sociol Health Illn. 2019. PMID 30461359
  14. Davis SR, et al. Path to diagnosis of severe asthma: qualitative exploration. J Asthma Allergy. 2024. PMID 39184910
  15. Goddard BMM, et al. Parents’ decision-making during a child’s attack: qualitative review. J Pediatr Nurs. 2022. PMID 35967097
  16. Persaud PN, et al. Burden of corticosteroid adverse effects and quality of life. J Allergy Clin Immunol Pract. 2023. PMID 37643678
  17. Clark VL, et al. Patient experience of severe-asthma add-on pharmacotherapy. J Asthma Allergy. 2021. PMID 33758515
  18. Fawcett R, et al. Parent/carer experience managing childhood asthma: qualitative review. JBI Database System Rev Implement Rep. 2019. PMID 31090652
  19. Kang HQ, et al. Experience of shared decision-making: systematic review and metasynthesis. Patient Educ Couns. 2024. PMID 38613765
  20. Hyland ME, et al. Construction and validation of the Severe Asthma Questionnaire. Eur Respir J. 2018. PMID 29794132
  21. Mulvey C, et al. Patient-selected treatment goals in severe asthma. J Allergy Clin Immunol Pract. 2021. PMID 33577946
  22. Nakanishi Y, et al. Inhaler preference and asthma outcomes. J Asthma Allergy. 2022. PMID 36316999
  23. Liu TL, et al. Shared decision-making and time to pediatric exacerbation. J Asthma. 2018. PMID 28892418
  24. Gassasse Z, et al. Income, employment and asthma outcomes: systematic review and meta-analysis. Lancet Reg Health Eur. 2025. PMID 40688041
  25. Okelo SO. Racial inequities in asthma care. Pediatr Clin North Am. 2022. PMID 36220057
  26. Tyris J, et al. Social determinants and pediatric asthma healthcare use: systematic review. J Allergy Clin Immunol Pract. 2023. PMID 37455665
  27. Pinnock H, et al. Supported self-management: systematic meta-review. BMC Med. 2017. PMID 28302126
  28. Kew KM, et al. Shared decision-making for people with asthma. Cochrane Database Syst Rev. 2017. PMID 28972652
  29. McDonald CF. Patient and professional views on oral corticosteroids. Respirology. 2025. PMID 40799034
  30. Self-management interventions for asthma: systematic review and network meta-analysis. J Asthma. 2023. PMID 37500118